FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					- 01	Jecui	011 30(11)	טו נווכ	invesiment (onipany Ac	. 01 1340								
1. Name and Address of Reporting Person <u>HAMILTON CHRISTINE E</u>						2. Issuer Name and Ticker or Trading Symbol SAB Biotherapeutics, Inc. [SABS]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) I Director 10% Owner						
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 07/15/2024							Officer (give title below)			Other (s				
777 W 41ST ST					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
SUITE 401													Line) Form filed by One Reporting Person						
(Street) MIAMI BEACH FL 33140						Person									e than	One Repo	rting		
_					- ∣Rı	Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tak	ole I - Noi	n-Deriv	vative	e Se	curities	s Ac	quired, D	isposed (of, or Be	neficial	ly Owned	l					
1. Title of Security (Instr. 3) 2. Transc Date (Month/L						ar)	2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	on Dispose			Benefici Owned F	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code V	Amount	(A) or	Price	Reported Transact (Instr. 3	ion(s)			(Instr. 4)		
			Table II -	Deriva	ative	Seci	urities	Aca	uired, Dis	posed of	or Ben	eficially				<u> </u>			
									s, options										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
												Amount or							
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Number of Shares							
Stock Option (right to buy) ⁽¹⁾⁽⁶⁾	\$2.9	07/15/2024			A		20,000		(1)	07/15/2034	Common Stock	20,000	\$0	20,000)	D			
Stock Option (right to buy) ⁽²⁾⁽⁶⁾	\$5.4	07/15/2024			A		5,815		(2)	07/15/2034	Common Stock	5,815	\$0	5,815		D			
Stock Option (right to buy) ⁽³⁾⁽⁶⁾	\$2.9	07/15/2024			A		4,447		(3)	07/15/2034	Common Stock	4,447	\$0	4,447		D			
Stock Option (right to buy) ⁽⁴⁾⁽⁶⁾	\$5.4	07/15/2024			A		44,202		(4)	07/15/2024	Common Stock	44,202	\$0	44,202	2	I	By Spouse		
Stock Option (right to	\$2.9	07/15/2024			A		2,326		(5)	07/15/2034	Common Stock	2,326	\$0	2,326		I	By Spouse		

Explanation of Responses:

- 1. Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.
- 2. Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option are fully vested.
- 3. Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.
- 4. Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option are fully vested.
- 5. Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.
- 6. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

/s/ Christine E. Hamilton

07/17/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.